Patients responding to one form of hormonal treatment had a greater likelihood of responding to subsequent hormonal manipulations. Additive hormonal therapy may provide effective palliation in males with advanced breast...
[3] Galanti D, Inno A, La Vecchia M, et al. Current treatment options for HER2-positive breast cancer patients with brain metastases. Crit Rev Oncol Hematol. 2021 May;161:103329. [4] Garcia-Alvarez A, Papakonstantinou A, Oliveira M. Br...
[7] Brufsky AM, Mayer M, Rugo HS, et al. Central nervous system metastases in patients with HER2-positive metastatic breast cancer: incidence, treatment, and survival in patients from registHER. Clin Cancer Res. 2011 Jul ...
[3] Huo X, Shen G, Wang T, et al. Treatment options for patients with human epidermal growth factor 2-positive breast cancer brain metastases: A systematic review and meta-analysis. Front Oncol. 2023;13:1003565. [4] Zimmer AS, Van Swearingen AED, Anders CK. HER2-positive breast cancer ...
2. Saini KS, et al. Beyond trastuzumab: new treatment options for HER2-positive breast cancer. Breast. 2011;20(Suppl 3):S20–7. 3. Capelan M, et al. Pertuzumab: new hope for patients with HER2-positive breast cancer. Ann Oncol. 2013;24(2):273–82. ...
Hatem Soliman, MD, discusses the current first-line treatment options for patients with HER2-positive breast cancer.
Over the past 2 decades, there has been an extraordinary progress in the regimens developed for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer. Trastuzumab, pertuzumab, lapatinib, and ado-trastuzumab emtansine (T-DM1) are commonly recommended anti-HER2 ...
[1]Li Y, Tong Z, Wu X, et al. Real-world treatment patterns and outcomes of pyrotinib-based therapy in patients with HER2-positive advanced breast cancer (PRETTY): A nationwide, prospective, observational study. Int J Cancer. 2023 Aug 6. ...
Sara A. Hurvitz, MD, reflects on key pivotal trials and recent regulatory decisions that have propelled progress in metastatic HER2-positive breast cancer. Sara A. Hurvitz, MD The year 2020 saw a myriad of promising studies that resulted in several FDA-approved options for patients wit...
for the use of anti-HER2 agents alone and in combination, examines the latest advances in HER2-targeted drugs and how they may be best applied in clinical practice, and provides guidance on optimal sequencing of the growing array of therapeutic options for HER2-positive breast cancer.doi...